Patients Treated with Fayuvi Gene Therapy | MPS IIIA | Observational Study | Ultragenyx
Page last updated: October 5, 2026 Page reviewed by: Dr. Cara O'Neill, FAAPFor web accessibility options: Click/tap the floating blue icon on the right.Clinical Trial Summary The UX111-CL401 MPS IIIA Disease Monitoring Program is a prospective, multicenter, long term...



